About Trod Medical

Trod Medical is a Venture Capital backed privately held company focused on the development and commercialization of tools for use in the focal ablation of soft tissues. The company was founded in 2006 with initial in-vivo studies undertaken during 2007 and first in man studies were completed in 2010.

Trod Medical obtained a 510K clearance from the FDA in 2008 and a CE mark for its Encage™ Focal Ablation Device in 2015.


To be a leader in the field of focal therapy.


To delivercutting edge tools to facilitate the delivery of focal therapy supported by solid clinical evidence and customer support.

Andre S. Faure MD - CEO

Dr. Faure is Trod Medical's founder and the inventor of EncageTM RF Focal ablation device. Dr. Faure has a surgical background and developed, over the years, significant knowledge in ablative technologies.

Andre successfully managed the EncageTM Focal ablation device through development, clinical and regulatory phases and led Trod Medical through Seed, Series A and Series B investment rounds.

Prior to founding Trod Medical, Andre led several multi-national R&D programs in the field of Medical Devices. Andre has about 15 years experience in Medical Devices development and about 10 years experience in Venture Capital backed ventures.

Dr. Faure holds several granted patents in Medical Device field.

Pierre Gillet Finance Director

As Finance Director of Trod Medical since 2013 Pierre Gillet has over 15 years experience within financial market and private equity industry. Prior to joining Trod Medical, he was investment manager at Vesale Partners, an independant private equity firm specialized in healthcare. Before he worked for 12 years in the IT venture team as investment manager at Société Générale Asset Management, then Amundi Private Equity Funds.

Benjamin Klein

Benjamin has a master's degree in Biomedical Engineering from the University of Franche-Comté (ISIFC, France). High skilled in ISO 13485 and FDA regulation; CE Mark approval and 510k clearance as well as in Medical device clinical evaluation.

He was, during his first professional years, a project leader in a small business biomedical company, Alcis, leading different projects from the design to the commercialization of several medical devices from class I to III.

Through his young career, he had the opportunity to build up a biomedical company named Lafayette Medical developing an implant for a mini-invasive treatment of female stress urinary incontinence. And he was, during a year, assistant lecturer at University of Franche-Comté (ISIFC, France) talked about project management; design control; biocompatibility & biomaterials; medical device clinical evaluation; risk analysis; internal audit.

Benjamin acquired about 10 years experience in Medical Devices development in different key positions including Project Manager as well as Quality Assurance & Regulatory Affairs Manager, consistently exceeded company objectives achieving operating management.

Dr. Thomas Mann

Dr Mann is Managing Director of DHF ltd. He had Chief Executive roles in the National Health Service and Private Sector Healthcare organisations. He has had 11 years of front line clinical experience and has since managed or consulted in acute care and mental health services, in procurement, delivery and strategy; in the voluntary and private sectors. His has worked in the UK the USA, South Africa and Europe. Tom qualified as a doctor from London University . He worked in Whitehall as a policy lead for the Department of Health on NHS reforms and performance management until his appointment as Head of Public Health Division for England. He led the Clinical Governance programme and devised the BMJ's Clinical Evidence publication. He led major service reorganisations including Children's, Mental Health, Cancer Services and Heart Disease.

Tom was Director of the National Implementation Team and after completing the first ISTC contracts he became CEO of Capio UK a hospital group with 34 hospitals and a turnover of £360m . He left to found DHF to bring expert health care teams together to advise across the private and public sector interface. DHF has most recently been involved in hospital efficiency improvement, advising on strategic investments and developing tariffs for specialist services.

Stephane Verdood

Stephane has an MBA and a Master's degree in commercial engineering from the Catholic University of Leuven.

Stephane is a recognized venture capitalist. He started his career with Arthur Andersen as information technology auditor. After having led the mergers and acquisitions division of Arthur Andersen in Belgium from 1989 to 1995, he founded and led Arthur Andersen's business consulting division in Belgium and Luxembourg. He served on the European Board of Partners of Arthur Andersen.

Since October 2000, before he joined Vesalius Biocapital, Stephane has been active as a venture coach for early-stage companies. He was a founder and managing partner at Value4Growth, a specialized Life Science consulting firm supporting start-up companies in all aspects of company formation, product strategy and fund raising.

Stephane is a founding partner of Vesalius Biocapital. Since 2007 he has invested in more than 15 biotech companies.

During his career he has worked in the US, Switzerland, France, the Netherlands, the UK and Portugal.

Frank Bulens

Frank joined Capricorn Venture Partners in 2009 and is a partner and member of its management committee and board of directors. Previously, he was a member of the life science venture capital team at Gimv (Antwerp, Belgium), senior scientific advisor at IWT, a research fund organisation in Brussels. Frank is an engineer chemistry/biochemistry and obtained a Master Degree as well as a PhD in Medical Sciences at the University of Leuven, Belgium.

His past board memberships involved companies such as Ablynx (Euronext Brussels, ABLX), Innate Pharma (Euronext Paris, IPH), Aclara Biosciences (listed on Nasdaq, ACLA, subsequently acquired), Fovea Pharmaceuticals (acquired by Sanofi-Aventis), Inpharmatica (acquired by Galapagos), Arrow Therapeutics (acquired by AstraZeneca) and X-Ceptor in the US (acquired by Exelixis).

Current board memberships include Sequana Medical (Switzerland), Trinean (Belgium), TROD Medical (Belgium) and Prosonix (UK, observer).

Michael Brock Chairman

Michael Brock has a Master Degree in Electronics engineering from Danish Technical University in 1979. Until the mid-nineties he was working with innovation and business development at Brüel&Kjær in Denmark - the global leader within sound and vibration measurements for industrial and environmental applications. In 1996, Michael became President & CEO of Madsen Electronics - a company within audiological measuring equipment - acquired several other related companies and finally founding a new consolidated company, Otometrics. In 2004 Michael became President & CEO for BK Medical - the global leader in the field of diagnostic ultrasound systems for urology - mainly prostate imaging - and surgery. During the years with BK Medical, Michael orchestrated a portfolio of innovative product launches enabling the company to grow significantly and thus consolidate its leading position in urology and prostate ultrasound. Since 2012 Michael has moved his career towards mainly board assignments, and he is today engaged in several companies in the medical field - hereunder as Chairman for Supersonic Imagine (Ultrasound Imaging, France) and DDD Diagnostic (Gamma Cameras, Denmark).